<DOC>
	<DOCNO>NCT00896025</DOCNO>
	<brief_summary>This propose study multi-center open label study determine N-acetylcysteine survival benefit patient ALF .</brief_summary>
	<brief_title>Study N-Acetylcysteine Acute Liver Failure ( ALF )</brief_title>
	<detailed_description>Patients admit study site carefully define criterion acute liver failure think acetaminophen toxicity , mushroom poisoning , pregnancy-related liver failure , malignancy eligible . Each patient receive intravenously solution 5 % dextrose water contain N-acetylcysteine , begin dose 150 mg/kg bodyweight 250 ml 5 % dextrose one hour , decline dos total 72 hour . Care patient consideration transplantation clinical decision affect study use study drug placebo .</detailed_description>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>Liver Failure , Acute</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Written Informed consent patient 's next kin Altered mentation degree ( encephalopathy ) Evidence moderately severe coagulopathy ( INR ≥ 1.5 ) A presume acute illness onset less 26 week Admitted study site hospital intensive care unit acute liver failure evaluate started treatment within first 24 hour hospitalization All subject 18 70 year The NIH guideline inclusion woman minority subject observe Patients less age 18 70 year age Acetaminophen mushroom poisoning induce liver failure Patients diagnosis shock liver ( ischemic hepatopathy ) Acute liver failure pregnancy HELLP syndrome ALF think secondary intrahepatic malignancy Cerebral herniation Intractable arterial hypotension Severe sepsis ( temperature &gt; 39º C and/or significant bacteremia ) present time enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Liver disease</keyword>
</DOC>